Identification
- Summary
Clonixin is an NSAID used to relieve pain associated with arthritis, migraines, and various soft tissue disorders.
- Generic Name
- Clonixin
- DrugBank Accession Number
- DB09218
- Background
Clonixin is a non-steroidal anti-inflammatory drug.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Clonixin (DB09218)
- Weight
- Average: 262.69
Monoisotopic: 262.0509053 - Chemical Formula
- C13H11ClN2O2
- Synonyms
- Clonixin
- clonixino
- External IDs
- CBA 93626
- SCH-10304
Pharmacology
- Indication
Indicated for use in the management of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Migraine •••••••••••• ••••••• •••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Clonixin is a non-steroidal anti-inflammatory drug (NSAID) similar in structure to Diclofenac. It produces vasodilation and analgesia.
- Mechanism of action
The mechanism of clonixin does not appear to have been investigated on a molecular level. It is presumed to function similarly to other NSAIDs by inhibiting cycloxygenase enzymes 1 and 2 resulting in a reduction in prostaglandin production.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Clonixin may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Abciximab. Acebutolol Clonixin may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Clonixin. Acemetacin The risk or severity of adverse effects can be increased when Clonixin is combined with Acemetacin. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Clonixin lysine 06PW4M190R 55837-30-4 CVNFYQCHAWFYQI-ZSCHJXSPSA-N - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image BENRELAX CÁPSULA BLANDA Clonixin lysine (125 mg) + Cyclobenzaprine hydrochloride (5 mg) Capsule, liquid filled Oral TECNOQUIMICAS S.A. 2020-11-26 Not applicable Colombia 
CLONIXINATO / CICLOBENZAPRINA 125MG/5MG Clonixin lysine (125 mg) + Cyclobenzaprine hydrochloride (5 mg) Capsule, liquid filled Oral TECNOQUIMICAS S.A. 2020-11-26 Not applicable Colombia DORIXINA® RELAX COMPRIMIDOS RECUBIERTOS Clonixin lysine (125 mg) + Cyclobenzaprine hydrochloride (5 mg) Tablet, coated Oral MEGA LABS S.A. 2006-11-10 Not applicable Colombia
Categories
- Drug Categories
- Agents causing hyperkalemia
- Agents that produce hypertension
- Amino Acids
- Amino Acids, Basic
- Amino Acids, Diamino
- Amino Acids, Peptides, and Proteins
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antirheumatic Agents
- Nephrotoxic agents
- Nicotinic Acids
- Non COX-2 selective NSAIDS
- Peripheral Nervous System Agents
- Pyridines
- Sensory System Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyridinecarboxylic acids. These are compounds containing a pyridine ring bearing a carboxylic acid group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Pyridinecarboxylic acids and derivatives
- Direct Parent
- Pyridinecarboxylic acids
- Alternative Parents
- Aniline and substituted anilines / Toluenes / Aminopyridines and derivatives / Chlorobenzenes / Aryl chlorides / Imidolactams / Vinylogous amides / Heteroaromatic compounds / Amino acids / Secondary amines show 8 more
- Substituents
- Amine / Amino acid / Amino acid or derivatives / Aminopyridine / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Azacycle / Benzenoid show 21 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- organochlorine compound, aminopyridine, pyridinemonocarboxylic acid (CHEBI:76200)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- V7DXN0M42R
- CAS number
- 17737-65-4
- InChI Key
- CLOMYZFHNHFSIQ-UHFFFAOYSA-N
- InChI
- InChI=1S/C13H11ClN2O2/c1-8-10(14)5-2-6-11(8)16-12-9(13(17)18)4-3-7-15-12/h2-7H,1H3,(H,15,16)(H,17,18)
- IUPAC Name
- 2-[(3-chloro-2-methylphenyl)amino]pyridine-3-carboxylic acid
- SMILES
- CC1=C(NC2=C(C=CC=N2)C(O)=O)C=CC=C1Cl
References
- General References
- Finch JS, DeKornfeld TJ: Clonixin: a clinical evaluation of a new oral analgesic. J Clin Pharmacol New Drugs. 1971 Sep-Oct;11(5):371-7. [Article]
- External Links
- PDB Entries
- 5l4i / 6gnr
- MSDS
- Download (82.2 KB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral Solution Intravenous 100 mg Capsule, liquid filled Oral Solution Parenteral 100.000 mg Solution Intramuscular Tablet Oral 125.0000 mg Gel Cutaneous 5.000 g Solution Intramuscular 100.000 mg Tablet Oral 125 mg Gel Topical 5 g Solution Intravenous Tablet, coated Oral Tablet Oral 125.00 mg Solution 100.000 mg Tablet Oral 125.000 mg Solution Parenteral 100 mg Tablet Oral 250.000 mg Solution Parenteral Solution Intramuscular 100.00 mg Tablet Oral 10.000 mg Capsule Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0535 mg/mL ALOGPS logP 3.59 ALOGPS logP 3.42 Chemaxon logS -3.7 ALOGPS pKa (Strongest Acidic) 1.88 Chemaxon pKa (Strongest Basic) 5.37 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 62.22 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 69.8 m3·mol-1 Chemaxon Polarizability 25.98 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 153.1681 predictedDeepCCS 1.0 (2019) [M+H]+ 155.52614 predictedDeepCCS 1.0 (2019) [M+Na]+ 161.61928 predictedDeepCCS 1.0 (2019)
Drug created at October 21, 2015 17:14 / Updated at May 05, 2021 20:31